Watchlist Price Alert

Cue Biopharma Inc. (CUE)

NASDAQ: CUE · Real-Time Price · USD

0.63

-0.01 (-2.17%)

At close: May 30, 2025, 3:59 PM

0.63

0.00%

After-hours: May 30, 2025, 03:59 PM EDT

-2.17% (1D)

Bid	0.63
Market Cap	47.47M
Revenue (ttm)	7.99M
Net Income (ttm)	-40.58M
EPS (ttm)	-0.64
PE Ratio (ttm)	-0.98
Forward PE	-1.49
Analyst	Buy

Ask	0.67
Volume	113,203
Avg. Volume (20D)	178,214
Open	0.64
Previous Close	0.64
Day's Range	0.63 - 0.66
52-Week Range	0.45 - 1.99
Beta	1.51

About CUE

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CUE

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CUE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+5.35%

Cue Biopharma shares are trading higher. Citizens ... Unlock content with Pro Subscription

2 months ago

-17.67%

Cue Biopharma shares are trading lower. The company reported FY24 financial results.

News

2 weeks ago · zacks.com

Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates

Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.25 per share a year ago.

1 month ago · zacks.com

Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know

Cue Biopharma (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · seekingalpha.com

Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)

Cue Biopharma, Inc. (NASDAQ:CUE ) Business Update Call April 15, 2025 4:30 PM ET Company Participants Eric Ribner - LifeSci Advisors Dan Passeri - Chief Executive Officer Lucinda Warren - Chief Busine...

2 months ago · zacks.com

Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates

Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.28 per share a year ago.